{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:22:12Z","timestamp":1778642532232,"version":"3.51.4"},"reference-count":25,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2018,6,11]],"date-time":"2018-06-11T00:00:00Z","timestamp":1528675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-n\/4.0\/"}],"funder":[{"name":"Marie Curie Innovative Training Network (ITN) grant, ADVance funded by European Commission supported LK.","award":["(FP7-290002)"],"award-info":[{"award-number":["(FP7-290002)"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:p>Oncolytic adenoviral immunotherapy activates the innate immune system with subsequent induction of adaptive tumor\u2010specific immune responses to fight cancer. Hence, oncolytic viruses do not only eradicate cancer cells by direct lysis, but also generate antitumor immune response, allowing for long\u2010lasting cancer control and tumor reduction. Their therapeutic effect can be further enhanced by arming the oncolytic adenovirus with costimulatory transgenes and\/or coadministration with other antitumor therapies. ONCOS\u2010102 has already been found to be well tolerated and efficacious against some types of treatment\u2010refractory tumors, including mesothelin\u2010positive ovarian cancer (NCT01598129). It induced local and systemic CD8+ T\u2010cell immunity and upregulated programmed death ligand 1. These results strongly advocate the use of ONCOS\u2010102 in combination with other therapeutic strategies in advanced and refractory tumors, especially those expressing the mesothelin antigen. The in vivo work presented herein describes the ability of the oncolytic adenovirus ONCOS\u2010102 to induce mesothelin\u2010specific T\u2010cells after the administration of the virus in bagg albino (BALB\/c) mice with mesothelin\u2010positive tumors. We also demonstrate the effectiveness of the interferon\u2010\u03b3 the enzyme\u2010linked immunospot (ELISPOT) assay to detect the induction of T\u2010cells recognizing mesothelin, hexon, and E1A antigens in ONCOS\u2010102\u2010treated mesothelioma\u2010bearing BALB\/c mice. Thus, the ELISPOT assay could be useful to monitor the progress of therapy with ONCOS\u2010102.<\/jats:p>","DOI":"10.1002\/jmv.25229","type":"journal-article","created":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T15:01:11Z","timestamp":1527174071000},"page":"1669-1673","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Antitumor\u2010specific T\u2010cell responses induced by oncolytic adenovirus ONCOS\u2010102 (AdV5\/3\u2010D24\u2010GM\u2010CSF) in peritoneal mesothelioma mouse model"],"prefix":"10.1002","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1887-6361","authenticated-orcid":false,"given":"Lukasz","family":"Kuryk","sequence":"first","affiliation":[{"name":"Department of Clinical Science Targovax Oy  Helsinki Finland"},{"name":"Department of Virology National Institute of Public Health\u2014National Institute of Hygiene  Warsaw Poland"},{"name":"Drug Research Program ImmunoVirothearpy Lab, Faculty of Pharmacy, University of Helsinki  Helsinki Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne\u2010Sophie W.","family":"M\u00f8ller","sequence":"additional","affiliation":[{"name":"Department of Clinical Science Targovax ASA  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5001-7826","authenticated-orcid":false,"given":"Mariangela","family":"Garofalo","sequence":"additional","affiliation":[{"name":"Drug Research Program ImmunoVirothearpy Lab, Faculty of Pharmacy, University of Helsinki  Helsinki Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4901-3796","authenticated-orcid":false,"given":"Vincenzo","family":"Cerullo","sequence":"additional","affiliation":[{"name":"Drug Research Program ImmunoVirothearpy Lab, Faculty of Pharmacy, University of Helsinki  Helsinki Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sari","family":"Pesonen","sequence":"additional","affiliation":[{"name":"Department of Clinical Science Targovax Oy  Helsinki Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramon","family":"Alemany","sequence":"additional","affiliation":[{"name":"Catalan Institute of Oncology IDIBELL  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Jaderberg","sequence":"additional","affiliation":[{"name":"Department of Clinical Science Targovax ASA  Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,6,11]]},"reference":[{"key":"e_1_2_7_1_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-3-34"},{"key":"e_1_2_7_1_3_1","doi-asserted-by":"publisher","DOI":"10.12669\/pjms.296.3938"},{"key":"e_1_2_7_1_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00520.x"},{"key":"e_1_2_7_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.08.028"},{"key":"e_1_2_7_1_6_1","first-page":"51","article-title":"New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials","volume":"7","author":"Kotova S","year":"2015","journal-title":"Cancer Manag Res"},{"key":"e_1_2_7_1_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4663"},{"key":"e_1_2_7_1_8_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.20172"},{"key":"e_1_2_7_1_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00195"},{"key":"e_1_2_7_1_10_1","first-page":"571","article-title":"Oncolytic viruses & their specific targeting to tumour cells","volume":"136","author":"Singh PK","year":"2012","journal-title":"Indian J Med Res"},{"key":"e_1_2_7_1_11_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2014.001"},{"key":"e_1_2_7_1_12_1","unstructured":"KurykL.Strategies to Enhance Efficacy of Oncolytic Virotherapy[dissertation]. Helsinki Finland: University of Helsinki Faculty of Pharmacy Doctoral Programme in Biomedicine;2016."},{"key":"e_1_2_7_1_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0559"},{"key":"e_1_2_7_1_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1105429"},{"key":"e_1_2_7_1_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182715"},{"key":"e_1_2_7_1_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1017702"},{"key":"e_1_2_7_1_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0121-5"},{"key":"e_1_2_7_1_18_1","doi-asserted-by":"publisher","DOI":"10.4161\/21624011.2014.958937"},{"key":"e_1_2_7_1_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3001"},{"key":"e_1_2_7_1_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30228"},{"key":"e_1_2_7_1_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.161"},{"key":"e_1_2_7_1_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29048"},{"key":"e_1_2_7_1_23_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.11.7179"},{"key":"e_1_2_7_1_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.163"},{"key":"e_1_2_7_1_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01689-07"},{"key":"e_1_2_7_1_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2012.12.014"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.25229","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.25229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T14:33:56Z","timestamp":1694961236000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.25229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,11]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1002\/jmv.25229"],"URL":"https:\/\/doi.org\/10.1002\/jmv.25229","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,11]]},"assertion":[{"value":"2018-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-11","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}